HomeBusinessHealthcare360 Round: Health Care PFE & JNJ
360 Round: Health Care PFE & JNJ

Pfizer (PFE) is on track to generate strong revenue and operating cash flow in 2021, with a large contribution from its Covid-19 vaccine, says David Toung, Senior Analyst of Medical Devices and Healthcare Services at Argus Research. He, and Sel Hardy, Equity Analyst at CFRA Research discuss the outlook for health care stocks. CFRA has a strong buy rating on Pfizer with a $57 price target and a buy rating on Johnson & Johnson (JNJ) with a $189 price target. Tune in to find out more.

Trading 360

08 Oct 2021

ON AIR
4:00 am
Fast Market
replay
12:00 am
Fast Market
REPLAY
education
1:00 am
Your First Trade
REPLAY
1:30 am
Next Gen Investing
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Trading 360
REPLAY
ON AIR
4:00 am
Fast Market
REPLAY
5:00 am
Next Gen Investing
REPLAY
education
6:00 am
Your First Trade
REPLAY
6:30 am
Trading 360
REPLAY
7:30 am
Fast Market
REPLAY
8:30 am
Next Gen Investing
REPLAY
education
9:30 am
Your First Trade
REPLAY
10:00 am
Trading 360
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Your First Trade
REPLAY
1:30 pm
Trading 360
REPLAY
2:30 pm
Fast Market
REPLAY
3:30 pm
Next Gen Investing
REPLAY
education
4:30 pm
Your First Trade
REPLAY
5:00 pm
Trading 360
REPLAY
6:00 pm
Fast Market
REPLAY
7:00 pm
Next Gen Investing
REPLAY
education
8:00 pm
Your First Trade
REPLAY
8:30 pm
Trading 360
REPLAY
9:30 pm
Fast Market
REPLAY
10:30 pm
Next Gen Investing
REPLAY
education
11:30 pm
Your First Trade
REPLAY

Get Market Minute

Daily insights for every investor

FOLLOW US